March 17 (Reuters) – Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to co‑market semaglutide injections in the country ahead of the ingredient’s patent expiry.
Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite.
The upcoming patent expiry for semaglutide has triggered a rush among Indian drugmakers to develop cheaper versions to capture market share in the world’s most populous nation, which has the second-highest number of adults with diabetes after China.
Here are some key details:
(Reporting by Urvi Dugar in Bengaluru; Editing by Sherry Jacob-Phillips)
Comments